Patients can track their progress through several key indicators
20 Yet despite this heightened need, Black patients are far less likely to be prescribed GLP-1 products
These questions are not specific to altRx
It corresponds to the pharmacokinetic profile of weekly GLP-1 medications, maintaining blood levels within the therapeutic range
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
Dopamine, which acts as a neurotransmitter, is known to play a key role in movement control